يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Social participation"', وقت الاستعلام: 1.52s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المؤلفون: Cornwall KM; Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT, USA., Butterfield RJ; Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT, USA.; Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA., Hernandez A; Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT, USA., Heatwole C; Department of Neurology, University of Rochester Medical Center School of Medicine and Dentistry, Rochester, NY, USA., Johnson NE; Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT, USA.; Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA.

    المصدر: Journal of neuromuscular diseases [J Neuromuscul Dis] 2018; Vol. 5 (2), pp. 251-255.

    نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

    بيانات الدورية: Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101649948 Publication Model: Print Cited Medium: Print ISSN: 2214-3599 (Print) NLM ISO Abbreviation: J Neuromuscul Dis Subsets: MEDLINE

    مستخلص: Congenital muscular dystrophies (CMD) cause progressive muscle weakness resulting in severe motor disabilities. Previous studies focused on the effects of motor disability. Here, we explore other factors affecting health related quality-of-life (HRQOL) in CMD. Qualitative interviews were conducted with participant-parent dyads to identify symptoms having the greatest impact on HRQOL. Symptoms were classified into themes and domains representing physical, mental, social health, and disease specific issues. Social role limitations and specific activity impairment were frequently mentioned. A greater understanding of symptoms impacting HRQOL will provide a framework for improved clinical care and patient centered outcomes as new therapies are developed.

    SCR Disease Name: Bethlem myopathy; Muscular dystrophy congenital, merosin negative; Scleroatonic muscular dystrophy

  2. 2
    دورية أكاديمية

    المؤلفون: Van Heugten C; School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.; Department of Neuropsychology and Psychopharmacology, Maastricht University, Maastricht, The Netherlands., Meuleman S; Merem Rehabilitation Center De Trappenberg, Almere, The Netherlands., Hellebrekers D; School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands., Kruitwagen-van Reenen E; Center of Excellence in Rehabilitation Medicine, Brain Center Rudolf Magnus, University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, The Netherlands., Visser-Meily J; Center of Excellence in Rehabilitation Medicine, Brain Center Rudolf Magnus, University Medical Center Utrecht, and De Hoogstraat Rehabilitation, Utrecht, The Netherlands.

    المصدر: Journal of neuromuscular diseases [J Neuromuscul Dis] 2018; Vol. 5 (2), pp. 205-214.

    نوع المنشور: Journal Article

    بيانات الدورية: Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101649948 Publication Model: Print Cited Medium: Print ISSN: 2214-3599 (Print) NLM ISO Abbreviation: J Neuromuscul Dis Subsets: MEDLINE

    مستخلص: Background: Myotonic Dystrophy type 1 (DM1) is primarily a neuromuscular disease but can also have neuropsychological consequences (i.e.cognitive, emotional and behavioural) which can influence daily living and societal participation. Not much is known about the level of participation of DM1 patients and their relatives and the factors influencing participation. This information can guide the development of rehabilitation programs and identify those at risk of long-term participation problems.
    Objective: To investigate the level of participation of DM1 patients and their partners and the determinants.
    Methods: Cross-sectional study using the Utrecht Scale for Evaluation of Rehabilitation-Participation. Determinants were demographic, disease related, and neuropsychological characteristics. Spearman correlations and backward multiple regression analyses were performed.
    Results: Of the 66 DM1 participants, 54% reported severe fatigue and 47% apathy. Experienced participation restrictions were most prevalent in housekeeping (74%), sports (68%) and outdoor activities (55%). Participants were relatively satisfied with their level of participation, but dissatisfaction occurred mostly in housekeeping (58%), outdoor activities (55%), and sports (54%). Age and apathy were significant predictors of frequency of (R2 = 10.4) and restrictions in participation in the multivariate model (R2 = 14.4). Emotional functioning was the only significant predictor of satisfaction with participation (R2 = 23.8).
    Conclusions: A considerable number of DM1 patients have Central Nervous System-related problems such as fatigue and apathy in addition to neuromuscular restrictions. Risk factors for lower participation are age, apathy, and emotional problems. Physical as well as neuropsychological rehabilitation programs are recommended.

  3. 3
    دورية أكاديمية
  4. 4

    المساهمون: Section Neuropsychology, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: FPN NPPP I, Promovendi MHN, Klinische Neurowetenschappen

    المصدر: Journal of neuromuscular diseases, 5(2), 205-214. I O S Press

    الوصف: BACKGROUND: Myotonic Dystrophy type 1 (DM1) is primarily a neuromuscular disease but can also have neuropsychological consequences (i.e.cognitive, emotional and behavioural) which can influence daily living and societal participation. Not much is known about the level of participation of DM1 patients and their relatives and the factors influencing participation. This information can guide the development of rehabilitation programs and identify those at risk of long-term participation problems.OBJECTIVE: To investigate the level of participation of DM1 patients and their partners and the determinants.METHODS: Cross-sectional study using the Utrecht Scale for Evaluation of Rehabilitation-Participation. Determinants were demographic, disease related, and neuropsychological characteristics. Spearman correlations and backward multiple regression analyses were performed.RESULTS: Of the 66 DM1 participants, 54% reported severe fatigue and 47% apathy. Experienced participation restrictions were most prevalent in housekeeping (74%), sports (68%) and outdoor activities (55%). Participants were relatively satisfied with their level of participation, but dissatisfaction occurred mostly in housekeeping (58%), outdoor activities (55%), and sports (54%). Age and apathy were significant predictors of frequency of (R2 = 10.4) and restrictions in participation in the multivariate model (R2 = 14.4). Emotional functioning was the only significant predictor of satisfaction with participation (R2 = 23.8).CONCLUSIONS: A considerable number of DM1 patients have Central Nervous System-related problems such as fatigue and apathy in addition to neuromuscular restrictions. Risk factors for lower participation are age, apathy, and emotional problems. Physical as well as neuropsychological rehabilitation programs are recommended.

    وصف الملف: application/pdf

  5. 5

    المصدر: J Neuromuscul Dis

    الوصف: Congenital muscular dystrophies (CMD) cause progressive muscle weakness resulting in severe motor disabilities. Previous studies focused on the effects of motor disability. Here, we explore other factors affecting health related quality-of-life (HRQOL) in CMD. Qualitative interviews were conducted with participant-parent dyads to identify symptoms having the greatest impact on HRQOL. Symptoms were classified into themes and domains representing physical, mental, social health, and disease specific issues. Social role limitations and specific activity impairment were frequently mentioned. A greater understanding of symptoms impacting HRQOL will provide a framework for improved clinical care and patient centered outcomes as new therapies are developed.